Global Biopsy Devices Market Size and Forecast 2026–2034

The global healthcare industry is witnessing a profound shift toward early detection and precision diagnostics, and biopsy devices are at the center of this transformation. As cancer cases rise worldwide and diagnostic technologies become increasingly sophisticated, the demand for reliable, minimally invasive biopsy solutions continues to grow.

According to Renub Research, the Global Biopsy Devices Market, valued at US$ 3.02 Billion in 2025, is projected to reach US$ 5.02 Billion by 2034, expanding at a Compound Annual Growth Rate (CAGR) of 5.81% during 2026–2034. This growth trajectory reflects the critical role biopsy procedures play in confirming disease diagnosis, guiding treatment strategies, and improving patient survival outcomes.

Download Sample Report

Global Biopsy Devices Market Outlook

Biopsy devices are specialized medical tools used to extract tissue or cell samples from the human body for diagnostic examination. These devices are indispensable in identifying abnormal cellular activity, particularly in cancer, inflammatory disorders, autoimmune diseases, and infectious conditions.

Modern biopsy systems include:

Needle-based guns

Vacuum-assisted biopsy devices

Forceps and drill systems

Image-guided biopsy solutions integrated with ultrasound, CT, MRI, and mammography

These tools are commonly used for sampling tissues from the breast, lungs, prostate, liver, kidneys, and bone marrow. Compared to traditional surgical biopsies, modern minimally invasive techniques reduce patient discomfort, shorten recovery times, and lower complication risks.

Growing awareness about preventive healthcare, a rapidly aging global population, and advancements in healthcare infrastructure are further accelerating the adoption of biopsy devices worldwide.

Key Growth Drivers of the Global Biopsy Devices Market

1. Rising Prevalence of Cancer and Chronic Diseases

Cancer remains one of the leading causes of mortality worldwide. The increasing incidence of breast, lung, prostate, colorectal, and liver cancers has intensified the need for accurate diagnostic tools.

Recent global estimates indicate:

Around 20 million new cancer cases annually

Approximately 9.7 million cancer-related deaths per year

Nearly 53.5 million individuals living within five years of diagnosis

Projections suggest 33 million new cases annually by 2050

Biopsy procedures are the gold standard for confirming malignancies. As cancer screening programs expand and early detection becomes a public health priority, biopsy device demand continues to strengthen.

Additionally, chronic inflammatory and autoimmune disorders also require tissue sampling for definitive diagnosis, further supporting sustained market growth.

2. Advancements in Minimally Invasive and Image-Guided Technologies

Technological innovation is reshaping the biopsy landscape. The integration of imaging modalities—such as CT scans, MRI, ultrasound, and stereotactic guidance—has significantly enhanced procedural precision.

Minimally invasive biopsy techniques offer:

Reduced procedural pain

Lower infection risk

Faster patient recovery

Improved diagnostic accuracy

In January 2025, the Intersocietal Accreditation Commission introduced MRI image-guided prostate biopsy standards, reflecting the growing institutional emphasis on precision-guided procedures.

Furthermore, in May 2025, BiBB Instruments AB and TaeWoong Medical USA signed a Letter of Intent to expand commercialization of the EndoDrill GI Biopsy System in the U.S., highlighting continued innovation in endoscopic biopsy technology.

These developments reinforce physician confidence and promote widespread clinical adoption.

3. Expansion of Healthcare Infrastructure and Diagnostic Services

Emerging economies are investing heavily in hospital construction, diagnostic imaging centers, and oncology facilities. Public awareness campaigns and government-led cancer screening programs are expanding access to diagnostic services.

Private and public sector investments are improving:

Availability of advanced imaging technologies

Training of healthcare professionals

Access to outpatient diagnostic facilities

In July 2025, Agilus Diagnostics announced the launch of its second Genexus system in collaboration with FMRI, underscoring the expansion of molecular diagnostics capabilities.

The growing availability of diagnostic and imaging centers—particularly in urban and semi-urban regions—continues to stimulate biopsy device demand globally.

Market Challenges

High Cost of Advanced Biopsy Systems

Sophisticated image-guided biopsy devices require significant capital investment. Equipment costs, imaging integration, and procedure-related expenses may limit adoption in cost-sensitive regions.

In developing countries, limited reimbursement coverage and budget constraints can restrict widespread implementation of high-end biopsy technologies.

Risk of Procedural Complications and Regulatory Hurdles

Although generally safe, biopsy procedures carry risks such as bleeding, pain, infection, or tissue damage. Rare complications may require additional medical intervention.

Moreover, medical device manufacturers must navigate stringent regulatory frameworks across multiple countries. Compliance requirements can extend product approval timelines and increase R&D expenditures.

Segment Analysis

Biopsy Needles Market

Biopsy needles represent one of the most widely used product categories. Their minimally invasive nature, cost-effectiveness, and clinical efficiency make them central to diagnostic workflows.

Disposable biopsy needles are gaining popularity due to infection control benefits. Their application spans breast, liver, prostate, kidney, and lung tissue sampling.

Prostate Biopsy Devices Market

Rising cases of prostate cancer among aging male populations are driving demand for advanced prostate biopsy devices. Abnormal prostate-specific antigen (PSA) levels typically prompt tissue sampling for definitive diagnosis.

MRI-guided and fusion-guided biopsy systems are reducing infection rates and enhancing diagnostic accuracy, strengthening this segment’s growth outlook.

Lung Biopsy Devices Market

The growing incidence of lung cancer and respiratory disorders is fueling demand for lung biopsy devices. CT-guided and bronchoscopic biopsy procedures have significantly improved targeting accuracy and minimized complications such as pneumothorax.

Smoking prevalence and environmental pollution further reinforce the long-term growth potential of this segment.

Biopsy CT Scan Devices Market

CT-guided biopsy systems allow physicians to accurately target tumors in difficult-to-reach areas such as the lungs, liver, pancreas, and bones. High-resolution imaging enhances diagnostic confidence and reduces repeat procedures.

Although capital-intensive, these systems remain indispensable in advanced oncology centers.

Diagnostic & Imaging Centers as Key End-Users

Diagnostic and imaging centers are emerging as major end-users due to the shift toward outpatient and minimally invasive care. These centers are equipped with advanced ultrasound, MRI, and CT technologies, enabling efficient image-guided biopsy procedures.

The rapid expansion of private diagnostic networks in developing countries is contributing significantly to market growth.

Regional Insights

United States

The United States remains a dominant market due to advanced healthcare infrastructure, high cancer incidence, and strong reimbursement frameworks. Continuous technological innovation supports robust demand for biopsy needles, guns, and guidance systems.

United Kingdom

In the United Kingdom, public healthcare initiatives under the NHS actively promote cancer screening programs. Adoption of minimally invasive, image-guided biopsy technologies continues to rise, despite public healthcare budget constraints.

In July 2025, Olympus Corporation launched SecureFlex, a single-use fine needle biopsy device in the EMEA region, demonstrating innovation momentum across Europe.

India

India is emerging as a high-growth market driven by expanding healthcare infrastructure and increasing cancer awareness. Government initiatives and private sector investments are improving access to diagnostic services.

In December 2024, PanGIA Biotech partnered with Canary Oncoceutics to introduce AI-integrated liquid biopsy solutions for prostate cancer detection in India, marking a milestone in precision diagnostics.

Medical tourism and cost-effective biopsy technologies are expected to further strengthen India’s market position.

Saudi Arabia

Saudi Arabia’s biopsy devices market is expanding due to rising healthcare expenditure and oncology infrastructure development. Government-backed modernization initiatives are improving access to advanced diagnostics.

In February 2025, healthcare investments included the establishment of an Oncology Center of Excellence by Johns Hopkins Aramco Healthcare and expansion projects by Aster Pharmacy.

However, reliance on imported high-end equipment and cost considerations may present moderate challenges.

Competitive Landscape

Leading companies operating in the Global Biopsy Devices Market include:

Cardinal Health, Inc.

Hologic, Inc.

Danaher Corporation

Becton, Dickinson and Company

Boston Scientific Corporation

Medtronic plc.

CONMED Corporation

These companies focus on technological innovation, strategic collaborations, product launches, and geographic expansion to strengthen their global footprint. Competitive differentiation increasingly revolves around precision, safety, disposability, and integration with imaging technologies.

Market Segmentation Overview

By Product

Needle-Based Guns

Biopsy Guidance Systems

Biopsy Needles

Biopsy Forceps

Others

By Application

Breast Biopsy

Lung Biopsy

Prostate Biopsy

Liver Biopsy

Gastroenterology Biopsy

Others

By Technology

CT Scan

Stereotactic Guided

Ultrasound Guided

MRI Guided

Others

By End-User

Hospitals

Diagnostic & Imaging Centers

Others

By Region

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Final Thoughts

The Global Biopsy Devices Market is entering a phase of steady and sustainable expansion. Rising cancer incidence, technological advancements in minimally invasive and image-guided procedures, and expanding healthcare infrastructure are collectively driving demand.

While cost pressures and regulatory challenges persist, innovation in disposable systems, AI-assisted diagnostics, and precision-guided technologies will likely redefine future growth patterns.

With the market projected to rise from US$ 3.02 Billion in 2025 to US$ 5.02 Billion by 2034 at a CAGR of 5.81%, biopsy devices will remain fundamental to modern diagnostic medicine. As healthcare systems worldwide continue to prioritize early detection and personalized treatment, the biopsy devices industry is well-positioned to play a central role in shaping the future of global oncology and diagnostic care.